LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the
development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the
Company will release its third quarter 2017 financial results on Tuesday, November 7, 2017, before the U.S. financial markets
open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations,
shortly before 8:30 a.m. EST. The conference ID number is 6198027. The conference call can also be accessed on the Curis website at
www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates
for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas
and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision
oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA
pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including
PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is
currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
jdentzer@curis.com
Media Contact:
David Schull
Russo Partners
212-845-4271
david.schull@russopartnersllc.com
